

## Special Issue

# Recent Discoveries and Developments in RNA and DNA Vaccines

### Message from the Guest Editor

With a long history of humans fighting against disease, scientists developed a biological preparation called a vaccine during the 10th century. A vaccine provides an active acquired immunity to a particular infectious or malignant disease. The effectiveness and safety of vaccines are always a significant concern to humankind; thus, scientists have undertaken considerable efforts and performed many pre-clinical and clinical studies to verify these in the last 60 years. RNA or DNA vaccine discovery and development for preventive and therapeutic applications has evolved rapidly in the previous decade. This Special Issue will focus on the most recent advanced research related to RNA or DNA vaccine discovery and development for preventive and therapeutic applications to fight against infectious or malignant diseases. The safest and most efficient RNA or DNA applications underlining the advantages and disadvantages of current RNA or DNA vaccines will be discussed. Both research (in particular) and review articles proposing novelties or overviews, respectively, are welcome.

---

### Guest Editor

Prof. Dr. Hang Fai (Henry) Kwok

1. Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Avenida de Universidade, Taipa, Macau SAR 999078, China
2. Department of Biomedical Sciences, Faculty of Health Sciences, University of Macau, Avenida de Universidade, Taipa, Macau SAR 999078, China

---

### Deadline for manuscript submissions

closed (31 July 2025)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/si/184613](https://mdpi.com/si/184613)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

---

### Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College  
Roosevelt, 4331 CB Middelburg, The Netherlands

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Infectious Diseases)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).